Budimir Drakulic - BioSig Technologies, Chief Scientist

All Insiders . USA . 
Stock . BioSig Technologies, Common . Stakeholders . Insider . Budimir Drakulic
BSGM Stock  USD 1.34  0.04  3.08%   

Insider

Budimir Drakulic is Chief Scientist of BioSig Technologies, Common
Age 74
Phone203 409 5444
Webhttps://www.biosig.com

BioSig Technologies, Management Efficiency

The company has return on total asset (ROA) of (4.478) % which means that it has lost $4.478 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (59.7735) %, meaning that it created substantial loss on money invested by shareholders. BioSig Technologies,'s management efficiency ratios could be used to measure how well BioSig Technologies, manages its routine affairs as well as how well it operates its assets and liabilities.
BioSig Technologies, Common currently holds 452 K in liabilities with Debt to Equity (D/E) ratio of 0.45, which is about average as compared to similar companies. BioSig Technologies, has a current ratio of 1.2, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist BioSig Technologies, until it has trouble settling it off, either with new capital or with free cash flow. So, BioSig Technologies,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioSig Technologies, sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioSig to invest in growth at high rates of return. When we think about BioSig Technologies,'s use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Julie GannonVivos Therapeutics
N/A
Kristin CaltriderInogen Inc
56
Michael GaulBeyond Air
69
Mark FeinbergBluejay Diagnostics
N/A
Steven MertensNeuroone Medical Technologies
61
Giora MDBeyond Air
N/A
John McKunePulmonx Corp
48
Lisa PaulPulmonx Corp
60
CPA CPACytosorbents Crp
67
CPA CPANanoVibronix
68
William MDNuwellis
N/A
George ParrInogen Inc
53
Paul TalmoTela Bio
52
Bradford AmmanVivos Therapeutics
62
Agnes LeeInogen Inc
N/A
Danielle WatsonHeart Test Laboratories
42
Robert MDCytosorbents Crp
85
Harold MDNanoVibronix
70
Michael FavetNeuropace
54
Laurent DuhouxNuwellis
N/A
Rebecca DorenBeyond Air
N/A
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut. Biosig Technologies operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 50 people. BioSig Technologies, Common [BSGM] is traded as part of a regulated electronic over-the-counter service offered by the NASD. BioSig Technologies, is listed under Medical Equipment category by Fama And French industry classification.

Management Performance

Return On Equity-59.77
Return On Asset-4.48

BioSig Technologies, Leadership Team

Elected by the shareholders, the BioSig Technologies,'s board of directors comprises two types of representatives: BioSig Technologies, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioSig. The board's role is to monitor BioSig Technologies,'s management team and ensure that shareholders' interests are well served. BioSig Technologies,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioSig Technologies,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven CPA, Chief Officer
Frederick Hrkac, Executive President
John Sieckhaus, Chief Officer
Budimir Drakulic, Chief Scientist
Steven Buhaly, Chief Officer
Gray Fleming, Chief Officer
Andrew Ballou, Vice Relations
Kenneth MBA, CEO Founder
MBA MBA, CEO Founder
Brenda Castrodad, VP HR
Michael Fleming, Chief Officer

BioSig Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is BioSig Technologies, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-59.77
Return On Asset-4.48
Operating Margin(227.43) %
Current Valuation6.43 M
Shares Outstanding14.12 M
Shares Owned By Insiders17.59 %
Shares Owned By Institutions3.04 %
Number Of Shares Shorted461.7 K
Price To Earning(3.73) X
Price To Book36.58 X

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in BioSig OTC Stock

BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY